Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Flatiron Health

Biotech & Life Sciences · New York City, United States · Founded 2012 Unicorn

Oncology real-world data and evidence generation platform

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Revenue
$100–500M
Latest reported FY
Unlock exact value
Headcount
1–2k
Current team size
Unlock exact value

Investors

20 investors on Flatiron Health's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 17 investors entered at this stage
Series B+ 3 investors entered at this stage
Roche Venture Fund
Allen & Company
Roche

Global footprint

Where Flatiron Health has talent and traffic

AI talent share
3.8% of workforce is AI talent
(56 of 1,466 staff)
Core AI130.89%
Other AI432.93%
Non-AI workforce1,41096.18%
Workforce by country
10 countries with
team presence
🇺🇸 United States92.2%
🇬🇧 United Kingdom3.4%
🇩🇪 Germany2.2%
🇯🇵 Japan1.4%
🇮🇳 India0.2%
Top 5 of 10 shown
Web traffic by country
650K monthly visits
across markets
🇺🇸 United States92.7%
🇮🇳 India1.9%
🏳️ Puerto Rico0.9%
🇮🇪 Ireland0.6%
🇬🇧 United Kingdom0.5%
Top 5 markets shown

Patent intelligence

$8M patent portfolio · 34 active families

Estimated portfolio value
$8M
0.43% of valuation · 114.6× smaller than top peer Globus Medical ($930M)
34 active patent families
Where Flatiron Health innovates Data scienceData miningMedicineData libraryMedical record

Where Flatiron Health concentrates vs peers

Each axis is a top-10 topic across Flatiron Health and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Flatiron Health's 6 investments and acquisitions.

Every disclosed deal where Flatiron Health appeared as a backer or acquirer, 2018–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Flatiron Health's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Flatiron Health deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Flatiron Health's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about Flatiron Health

        An AI-synthesized read of the highest-engagement posts about Flatiron Health on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Flatiron Health on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.